AMYT Amryt Pharma Plc

 
TIDMAMYT 
 
 
   AMRYT PHARMA PLC 
 
   ("Amryt" or the "Company") 
 
   Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights 
 
   DUBLIN, Ireland, and Boston MA, September 21 2020, Amryt (Nasdaq: AMYT, 
AIM: AMYT), a global, commercial-stage biopharmaceutical company 
dedicated to developing and commercializing novel therapeutics to treat 
patients suffering from serious and life-threatening rare diseases, 
announces that an institutional investor has exercised subscription 
rights relating to 4,229,753 zero cost warrants (the "Warrants"). 
 
   These Warrants were issued in September 2019 as part of the Company's 
acquisition of Aegerion.  Certain institutional investors elected to 
receive Warrants to subscribe for new ordinary shares of GBP0.06 each 
("Ordinary Shares"), in place of the same number of Ordinary Shares, as 
consideration for the Company's acquisition of Aegerion and their equity 
investments in the Company in September 2019.  Each warrant entitles the 
holder to subscribe for one Ordinary Share for no additional 
consideration. 
 
   In order to satisfy the exercise of the Warrants, the Company will issue 
4,229,753 ordinary shares of GBP0.06 each (the "New Ordinary Shares") to 
the institutional investor. It is expected that admission to trading of 
the New Ordinary Shares on AIM will become effective, and that dealings 
in the New Ordinary Shares will commence at 8.00 a.m. BST on 22 
September 2020. 
 
   On admission of the New Ordinary Shares, the issued share capital of the 
Company will comprise 167,593,296 Ordinary Shares. The Company holds 
4,864,656 Ordinary Shares in treasury. Therefore, the total number of 
voting rights in the Company is 162,728,640. This figure may be used by 
shareholders as the denominator for the calculation by which they will 
determine if they are required to notify their interest in, or a change 
to their interest in, the Company under the FCA's Disclosure Guidance 
and Transparency Rules. The Company will also have in issue 8,966,520 
zero cost warrants. 
 
   Enquiries: 
 
 
 
 
Amryt Pharma plc                              +353 (1) 518 0200 
Joe Wiley, CEO 
 Rory Nealon, CFO/COO 
 
  LifeSci Advisors, LLC                       +1 (212) 915 2564 
Tim McCarthy 
 
  Consilium Strategic Communications       +44 (0) 20 3709 5700 
Amber Fennell, Matthew Neal, Ashley Tapp 
 
 
   About Amryt 
 
   Amryt is a biopharmaceutical company focused on developing and 
delivering innovative new treatments to help improve the lives of 
patients with rare and orphan diseases. Amryt comprises a strong and 
growing portfolio of commercial and development assets. 
 
   Amryt's commercial business comprises two orphan disease products. 
 
   Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct to a 
low-fat diet and other lipid-lowering medicinal products for adults with 
the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia 
("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the 
trade name Juxtapid(R)) and in the EU (under the trade name Lojuxta(R)). 
HoFH is a rare genetic disorder which impairs the body's ability to 
remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) 
from the blood, typically leading to abnormally high blood LDL 
cholesterol levels in the body from before birth - often ten times more 
than people without HoFH - and subsequent aggressive and premature 
cardiovascular disease. 
 
   Myalept(R) / Myalepta(R) (metreleptin) is approved in the US (under the 
trade name Myalept(R)) as an adjunct to diet as replacement therapy to 
treat the complications of leptin deficiency in patients with congenital 
or acquired generalized lipodystrophy (GL) and in the EU (under the 
trade name Myalepta(R)) for the treatment of leptin deficiency in 
patients with congenital or acquired GL in adults and children two years 
of age and above and familial or acquired partial lipodystrophy (PL) in 
adults and children 12 years of age and above for whom standard 
treatments have failed to achieve adequate metabolic control. 
Metreleptin is also approved for lipodystrophy in Japan. Generalised and 
partial lipodystrophy are rare disorders characterised by loss or lack 
of adipose tissue resulting in the deficiency of the hormone leptin, 
produced by fat cells and are associated with severe metabolic 
abnormalities including severe insulin resistance, diabetes, 
hypertriglyceridemia and fatty liver disease. 
 
   Amryt's lead development candidate, FILSUVEZ(R) is a potential treatment 
for the cutaneous manifestations of EB, a rare and distressing genetic 
skin disorder affecting young children and adults for which there is 
currently no approved treatment.  In September 2020, Amryt reported 
positive top line results from its pivotal global phase 3 trial of 
FILSUVEZ(R) in EB.  The primary endpoint of the trial was met (p-value = 
0.013). FILSUVEZ(R) has been granted Rare Pediatric Disease Designation 
and has also received a Fast Track Designation from the U.S. Food and 
Drug Administration. The global market opportunity for EB is estimated 
by the Company to be in excess of $1.0 billion. 
 
   In March 2018, Amryt in-licenced a preclinical gene-therapy platform 
technology, AP103, which offers a potential treatment for patients with 
Dystrophic Epidermolysis Bullosa, a subset of EB, and is also 
potentially relevant to other genetic disorders. 
 
   For more information on Amryt, including products, please visit 
www.amrytpharma.com. 
 
   This announcement contains inside information for the purposes of 
article 7 of the Market Abuse Regulation (EU) 596/2014. 
 
   The person making this notification on behalf of Amryt is Rory Nealon, 
CFO/COO and Company Secretary. 
 
   Financial Advisors 
 
   Shore Capital (Edward Mansfield, Daniel Bush, John More) are NOMAD and 
Joint Broker to Amryt in the UK. Stifel (Ben Maddison) are Joint Broker 
to the company in the UK.  Davy (John Frain, Daragh O'Reilly) act as 
Joint Broker to the company. 
 
   Forward-Looking Statements 
 
   Statements in this announcement with respect to Amryt's business, 
strategies, timing for completion of and announcing results from the 
EASE trial, the potential impact of closing enrollment in the EASE trial, 
as well as other statements that are not historical facts are 
forward-looking statements involving risks and uncertainties which could 
cause the actual results to differ materially from such statements. 
Statements containing the words "expect", "anticipate", "intends", 
"plan", "estimate", "aim", "forecast", "project" and similar expressions 
(or their negative) identify certain of these forward-looking 
statements. The forward-looking statements in this announcement are 
based on numerous assumptions and Amryt's present and future business 
strategies and the environment in which Amryt expects to operate in the 
future. Forward-looking statements involve inherent known and unknown 
risks, uncertainties and contingencies because they relate to events and 
depend on circumstances that may or may not occur in the future and may 
cause the actual results, performance or achievements to be materially 
different from those expressed or implied by such forward-looking 
statements. These statements are not guarantees of future performance or 
the ability to identify and consummate investments. Many of these risks 
and uncertainties relate to factors that are beyond each of Amryt's 
ability to control or estimate precisely, such as future market 
conditions, the course of the COVID-19 pandemic, currency fluctuations, 
the behaviour of other market participants, the outcome of clinical 
trials, the actions of regulators and other factors such as Amryt's 
ability to obtain financing, changes in the political, social and 
regulatory framework in which Amryt operates or in economic, 
technological or consumer trends or conditions. Past performance should 
not be taken as an indication or guarantee of future results, and no 
representation or warranty, express or implied, is made regarding future 
performance. No person is under any obligation to update or keep current 
the information contained in this announcement or to provide the 
recipient of it with access to any additional relevant information that 
may arise in connection with it. Such forward-looking statements reflect 
the Company's current beliefs and assumptions and are based on 
information currently available to management. 
 
 
 
 

(END) Dow Jones Newswires

September 21, 2020 06:00 ET (10:00 GMT)

Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025